NASDAQ:EPZM - Epizyme Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.00 -0.23 (-3.18 %)
(As of 11/21/2018 02:55 PM ET)
Previous Close$7.23
Today's Range$6.90 - $7.4037
52-Week Range$7.17 - $21.40
Volume401,375 shs
Average Volume589,542 shs
Market Capitalization$593.76 million
P/E Ratio-3.21
Dividend YieldN/A
Beta1.89
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EPZM
Previous Symbol
CUSIPN/A
Phone617-229-5872

Debt

Debt-to-Equity RatioN/A
Current Ratio7.48
Quick Ratio7.48

Price-To-Earnings

Trailing P/E Ratio-3.21
Forward P/E Ratio-3.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales55.42
Cash FlowN/A
Price / CashN/A
Book Value$2.17 per share
Price / Book3.23

Profitability

EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-64.87%
Return on Assets-55.18%

Miscellaneous

Employees131
Outstanding Shares79,170,000
Market Cap$593.76 million
OptionableOptionable

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme Inc (NASDAQ:EPZM) posted its earnings results on Friday, November, 2nd. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.07. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

10 equities research analysts have issued twelve-month price targets for Epizyme's stock. Their predictions range from $11.00 to $27.00. On average, they expect Epizyme's share price to reach $21.1111 in the next year. This suggests a possible upside of 201.6% from the stock's current price. View Analyst Price Targets for Epizyme.

What is the consensus analysts' recommendation for Epizyme?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

What are Wall Street analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:
  • 1. According to Zacks Investment Research, "Epizyme is in the process of reopening enrollment in all of its company-sponsored trials in the United States, including the follicular lymphoma (FL) EZH2 activating mutation cohort of its phase II non-Hodgkin lymphoma study for its lead candidate, tazemetostat's clinical studies after the FDA lifted partial clinical hold on it. Further, the company also delayed the filing of its first NDA for tazemetostat for the treatment of epithelioid sarcoma to the first half of 2019, instead of the fourth quarter of 2018. With no approved product in its portfolio, Epizyme is yet to generate revenues. However, the company's is making efforts to develop tazemetostat for a number of hematological malignancies and genetically defined solid tumors. The company presented encouraging new clinical data regarding tazemetostat’s anti-tumor activity and tolerability in follicular lymphoma and mesothelioma. Loss estimates have narrowed ahead of Q3 release." (10/16/2018)
  • 2. Cann analysts commented, "Epizyme’s Q2 loss per share of $0.42 was less than our estimated loss of $0.60. This primarily resulted from an unanticipated milestone payment of $10 million and lower than estimated operating expense of $42.3 million vs. our estimated $46.8 million. Importantly, the NDA for tazemetostat is now expected in H1 2019 rather than our prior expectation of year-end 2018. This results from Epizyme wanting to submit more mature data in the epithelioid sarcoma setting and wanting to have the clinical hold for tazemetostat resolved before filing with FDA." (8/2/2018)
  • 3. HC Wainwright analysts commented, "Valuation and risks. Our price target of $25 on Epizyme is based on a probability-adjusted sum-of-parts NPV-DCF: $21 EZH2 (NHL + INI-) + $1 DOT1L (MLL-R) + $3 cash. Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller- than-anticipated commercial opportunity due to market sizing, competition, and pricing. Epizyme, Inc." (6/27/2018)

Has Epizyme been receiving favorable news coverage?

Media stories about EPZM stock have trended somewhat positive recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Epizyme earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the stock's share price in the near future.

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
  • Mr. Matthew E. Ros, Chief Strategy & Bus. Officer (Age 51)
  • Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
  • Ms. Suzanne Fleming, Principal Financial Officer, Sr. VP of Fin., Treasurer & Principal Accounting Officer (Age 57)

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (12.21%), BlackRock Inc. (5.51%), FMR LLC (4.63%), Redmile Group LLC (2.84%), Jennison Associates LLC (2.78%) and Foresite Capital Management II LLC (1.81%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.

Which major investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Citadel Advisors LLC, Oracle Investment Management Inc., Opaleye Management Inc., TIAA CREF Investment Management LLC, Morgan Stanley, Macquarie Group Ltd. and Foresite Capital Management II LLC. View Insider Buying and Selling for Epizyme.

Which major investors are buying Epizyme stock?

EPZM stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Sofinnova Ventures Inc, Dimensional Fund Advisors LP, Redmile Group LLC, University of Notre Dame DU Lac, Sphera Funds Management LTD., AXA and BlackRock Inc.. View Insider Buying and Selling for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $7.00.

How big of a company is Epizyme?

Epizyme has a market capitalization of $593.76 million and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is http://www.epizyme.com.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (NASDAQ EPZM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel